Dear COMPPARE team, participants, stakeholders and friends,
I am pleased to announce that on May 3, 2022, UH Seidman Cancer Center enrolled our 2,250th COMPPARE participant! This means we are now 75% of the way through the accrual process, an exceptional accomplishment given the ongoing challenges presented by COVID-19. I am thankful for the COMPPARE administrative team as well as the research teams at all of our participating sites for helping to achieve this goal.
We are also excited to report that the Randomized Control Trial arm of the Proton Cohort closed on May 27, 2022 as we reached our goal of 600 patients. This is two months in advance of our anticipated closure date and I am deeply grateful to those patients, research staff, and physician investigators for their continued dedication to future generations of men with prostate cancer’s ability to make informed treatment decisions.
As we near the completion of COMPPARE’s overall enrollment objective – a total of 3,000 patients – we are beginning to reflect and evaluate what we’ve learned thus far in creating and carrying out a large, multi-institutional pragmatic trial. I am excited to not only analyze the data of the trial itself, but begin to look at ways we may be able to improve the research process for others moving forward.
To learn more about the COMPPARE study, visit https://comppare.org/about/study-details/.
In good health,